Cardiff Oncology shares plunge after Q2 earnings miss
HOUSTON - Core Laboratories N.V. (NYSE:CLB) reported first quarter earnings that fell short of analyst expectations, sending shares down 3.1% in after-hours trading.
The oil services company posted adjusted earnings per share of $0.14 for the quarter, missing the consensus estimate of $0.29. Revenue came in at $123.6 million, below analyst projections of $143.5 million and down 5% YoY.
Core Labs cited geopolitical conflicts, expanded sanctions, and pending tariffs as headwinds that impacted demand for its laboratory services and perforating product sales in Q1. These factors created "temporary operational inefficiencies" for the company, according to CEO Larry Bruno.
"In addition to the normal seasonal decline in client activity that typically occurs between the fourth and first quarters, Core Lab’s team navigated a volatile market," Bruno stated.
For the second quarter, Core Labs expects revenue between $128 million to $134 million, compared to the $128.9 million consensus estimate. The company projects Q2 EPS of $0.17 to $0.21.
Despite the earnings miss, Core Labs generated free cash flow of $3.9 million in Q1, up over 50% YoY. The company also reduced its net debt by $4.9 million during the quarter.
Core Labs will pay a quarterly dividend of $0.01 per share on May 27 to shareholders of record as of May 5.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.